Journal
ONCOIMMUNOLOGY
Volume 4, Issue 8, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2015.1026503
Keywords
CD161; germinal center; LLT1; natural killer cells; non-Hodgkin's B-cell lymphoma
Categories
Funding
- Novo Nordisk S/A
- Agence Nationale de Recherches sur le Syndrome de l'Immunodeficience-Acquise (SIDA)
- Ensemble contre le SIDA
- Fondation ARC
- Agence Nationale de la Recherche (ANR)
- Canceropole PACA
- Centre National de la Recherche Scientifique
- French Government (National Research Agency, ANR) through Investments for the Future LABEX SIGNALIFE: program [ANR-11-LABX-0028-01]
Ask authors/readers for more resources
Non-Hodgkin's lymphomas (NHLs) are malignant neoplasms which are clinically and biologically diverse. Their incidence is constantly increasing and despite treatment advances, there is a need for novel targeted therapies. Here, we identified Lectin-like transcript 1 (LLT1) as a biomarker of germinal center (GC)-derived B-cell NHLs. LLT1 identifies GC B cells in reactive tonsils and lymph nodes and its expression is maintained in B-cell NHLs which derive from GC, including Burkitt lymphoma (BL), follicular lymphoma (FL), and GC-derived diffuse large B-cell lymphoma (DLBCL). We further show that LLT1 expression by tumors dampens natural killer (NK) cell functions following interaction with its receptor CD161, uncovering a potential immune escape mechanism. Our results pinpoint LLT1 as a novel biomarker of GC-derived B-cell NHLs and as a candidate target for innovative immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available